Upcoming CATTI-MRM Cell Therapy Bootcamp
The MRM is excited to partner with the Canadian Advanced Therapies Training Institute (CATTI) to offer a hands-on workshop at McGill: Cell Therapy Bootcamp – Aseptic Techniques & Cleanroom Biomanufacturing for hPSC-based Therapeutics.
The 5-day course (Cell therapies on hPSC) is designed to teach the participants all the unit operations associated with the expansion of hPSCs in a 2D culture system while also focusing on the best practices for aseptic techniques, which are paramount when working in a clean room environment. In addition, we introduce and integrate aspects of GMP into the modules so that as the participants learn how to manipulate hPSCs as per industry practices they also get to practice elements of GMP.
The workshop will be offered on Campus and is designed for students/HQP with some experience with cell-culture.
More details about the date, requirements and selection process to come soon.
If you know someone in your lab who could benefit from this opportunity, please email us at email@example.com.
- The Canadian Advanced Therapies Training Institute (CATTI) is developing and scaling online and onsite GMP training programs that will facilitate an unprecedented capacity in Canada for efficient and rapid upskilling of the workforce required. CATTI aims to:
- Standardize the training curriculum for the needs of manufacturing sites to establish a quality standard for training focused on best practices
- De-risk the process of training & developing HQP to the level of autonomy
- Reduce the training burden by outsourcing it
- Accelerate the market readiness of trainees by offering specialized training
- Diminish the funds allocated for training per employee by maximizing efficiency
- Bridge the gap between the academic background qualifications and the market readiness of HQP
The Training Institute is led by a Consortium of two highly successful Networks of Centers of Excellence in Canada, one being CCRM, a Center of Excellence for the Commercialization of Research, and CellCAN, a Knowledge Mobilization Network. Their interest in joining efforts rely on the facts that manufacturing and commercializing CGT products requires a highly qualified workforce and that there is currently a dearth in finding such qualified personnel. A unique opportunity exists to leverage the strengths and synergies between those two well recognized organizations to contribute substantially to growing the cell and gene therapy sector. This partnership will solidify national assets and excellence in advanced biotherapeutics manufacturing under cGMP, and fill the dearth in available talent of HQP trained and qualified for workflow under aseptic conditions. It will also ensure job creation.